Moderna Climbs 13% After Analyst Upgrades to a Buy: Why MRNA is Still Rated a Hold at VectorVest

By |2024-01-03T17:25:19+00:00January 3rd, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , |

Shares of Moderna (MRNA) climbed 13% in yesterday’s trading session after being upgraded to a buy at Oppenheimer. The stock fell a bit in Wednesday’s trading session, but has since settled at around even on the day. Hartaj Singh and a team of analysts see dramatic upside potential over the next few years for [...]